A phase II, multi-centre, randomized, parallel group, baseline-and withdrawal-controlled study in 36 patients with primary aldosteronism to determine the dose-dependent efficacy,safety and tolerability of DP13 after a 2-week single-blind placebo run-in period followed by a randomized 8-week double-blind treatment period. After an additional single-blind, 2-week DP13 placebo withdrawal period, patients are switched to standard of care.
Study Name: DP13 – A Phase II Study in Patients With Primary Aldosteronism
Conditions: Primary aldosteronism
Interventions: Drug: DP-13
Locations: Ospedale Molinette, Torino, Italy, 10126
Study link: https://ClinicalTrials.gov/show/NCT04007406
To search for other studies by topic, location, or status, go to our Clinical Studies page.